低剂量阿司匹林对逆转老年人衰弱状态无效:ASPREE随机临床试验二次分析
本研究为ASPREE随机安慰剂对照试验的事后亚组分析,纳入基线处于衰弱前期或衰弱期的社区老年人,中位随访4.7年。结果显示,低剂量阿司匹林与安慰剂组在衰弱状态逆转率上无显著差异(FFP-HR 1.00,95%CI 0.92-1.07;FI-HR 1.00,95%CI 0.94-1.07),且纵向衰弱轨迹变化亦无差异。结论认为低剂量阿司匹林不能逆转衰弱。
要点
- 低剂量阿司匹林未能逆转衰弱前期或衰弱状态。
- 阿司匹林既未改善也未加重衰弱严重程度。
- 年龄、性别、种族及病史等亚组均未见效应修饰。
核心结论
- 低剂量阿司匹林对衰弱前期和衰弱老年人无逆转衰弱的作用。
研究设计与样本
- 本研究为ASPREE随机安慰剂对照试验的事后亚组分析,纳入社区居住的65岁及以上老年人,中位随访4.7年(IQR 3.6-5.7年)。
- 衰弱采用Fried衰弱表型(FFP)和缺陷累积衰弱指数(FI)两种经验证工具评估,衰弱逆转定义为向更轻状态转变。
主要发现
- 在FFP分析纳入的6595名参与者和FI分析纳入的8766名参与者中,阿司匹林组与安慰剂组的衰弱逆转率无显著差异(FFP-HR 1.00,95%CI 0.92-1.07;FI-HR 1.00,95%CI 0.94-1.07)。
- 随时间变化的FFP计数(β=0.014,SE=0.007,P=.06)和FI评分(β=0.0004,SE=0.004,P=.37)在两组间无显著差异,提示阿司匹林既未逆转也未加重衰弱严重程度。
- 亚组分析显示年龄、性别、种族和病史等衰弱风险因素均未对效应产生修饰作用。
临床怎么用
- 对于衰弱前期或衰弱的老年人,不应期望通过低剂量阿司匹林来逆转衰弱状态。
- 需探索其他抗炎药物用于衰弱管理的可能性。
局限性
- 本研究为事后亚组分析,可能存在选择偏倚和残余混杂。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic low-grade inflammation is hypothesised as a central driver of frailty. This study aims to evaluate whether low-dose aspirin can reverse frailty status among initially prefrail/frail older adults. METHODS: This was a post hoc subgroup analysis of the Aspirin in Reducing Events in the Elderly (ASPREE), a randomised, placebo-controlled trial, involving community-dwelling adults aged ≥65 years. The median (Interquartile range) follow-up was 4.7 (3.6-5.7) years. We included participants who were prefrail or frail at baseline, with frailty assessed using two validated measures: the Fried Frailty Phenotype (FFP) and the Deficit-Accumulation Frailty Index (FI). Frailty reversal was defined as a transition to a less severe state (from frail to prefrail/nonfrail, prefrail to nonfrail). The discrete-time survival model was used for outcome analysis; linear mixed-effects models compared longitudinal frailty trajectories between the treatment arms. RESULTS: Among 6595 and 8766 participants included in the FFP and FI analyses, respectively, there was no significant difference in frailty status reversal between aspirin and placebo groups (FFP-HR: 1.00, 95% CI: 0.92-1.07; FI-HR: 1.00, 95% CI: 0.94-1.07). No significant difference was found in the change of FFP counts (β = 0.014, SE = 0.007, P = .06) and FI score (β = 0.0004, SE = 0.004, P = .37) between the aspirin and placebo groups over time, suggesting that aspirin neither reversed nor worsened frailty severity. Subgroup analyses revealed no effect modification by frailty risk factors such as age, sex, race and medical history. CONCLUSION: Low-dose aspirin has no effect in reversing frailty among prefrail and frail individuals. The findings highlight the need to explore alternative anti-inflammatory medications for frailty management.
引用
- Handono AP, Ryan J, Setiawan F, et al. The effect of low-dose aspirin on reversing frailty status in older prefrail and frail adults: a secondary analysis of the ASPREE randomised clinical trial. Age Ageing. 2025. PMID: 40996142. doi:10.1093/ageing/afaf271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。